## LLY: Eli Lilly and Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.0% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($1024.36)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Comeback Town: Huntsville didn’t need UAB to win Eli Lilly — and that should terrify Birmingham**
- Source: AL.com | 20251228T141926 | Bullish | Relevance: 100%
- Huntsville secured a major Eli Lilly pharmaceutical plant investment of over $6 billion, bringing 3,450 jobs, prompting a critical look at Birmingham's economic development strategies. The article argues that Birmingham's flagship institution, UAB, lags in commercializing research, hindering the city's ability to attract similar high-value projects. It suggests Birmingham needs to prioritize true economic development over community development and foster regional cooperation, much like the state did for the Mercedes-Benz project in 1993.

**2. Is Eli Lilly Pulling Ahead in the Weight Loss Drug Battle?**
- Source: Finviz | 20251225T120500 | Bullish | Relevance: 100%
- Eli Lilly appears to be leading the highly competitive weight loss drug market, primarily due to its strong product lineup and robust pipeline, including Zepbound which outperforms competitors. The company's recent clinical successes with drugs like orforglipron and retatrutide position it well ahead of rivals such as Novo Nordisk. Eli Lilly is expected to maintain its significant growth in both top and bottom lines for the foreseeable future.

**3. Cwm LLC Has $75.20 Million Stock Position in Eli Lilly and Company $LLY**
- Source: MarketBeat | 20251227T100757 | Bullish | Relevance: 100%
- Cwm LLC significantly increased its stake in Eli Lilly and Company by 11.1% in Q3, now holding 98,555 shares valued at $75.20 million. Eli Lilly reported a strong quarter with earnings beating estimates and raised its FY2025 EPS guidance, alongside increasing its quarterly dividend. The stock currently has a "Moderate Buy" consensus rating from analysts, with several firms raising price targets due to positive new drug data and financial performance.

**4. Private Trust Co. NA Sells 2,448 Shares of Eli Lilly and Company $LLY**
- Source: MarketBeat | 20251226T110818 | Bullish | Relevance: 100%
- Private Trust Co. NA reduced its stake in Eli Lilly and Company (LLY) by 20.4% in the third quarter, selling 2,448 shares and retaining 9,531 shares valued at $7.27 million. Eli Lilly recently reported strong earnings, beating analyst expectations, and has a "Moderate Buy" consensus rating with an average price target of $1,155.36. The company also announced an increase in its quarterly dividend.

**5. Eli Lilly and Company $LLY Stake Raised by Welch Group LLC**
- Source: MarketBeat | 20251225T130828 | Bullish | Relevance: 99%
- Welch Group LLC increased its stake in Eli Lilly and Company by 15.4% during the third quarter, bringing its total holdings to 7,514 shares valued at $5.73 million. Eli Lilly (NYSE:LLY) reported strong Q3 earnings, beating analyst expectations with an EPS of $7.02 and revenue of $17.6 billion, and raised its quarterly dividend. Institutional investors collectively own 82.53% of the company's stock, with Vanguard Group Inc. being a significant holder.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $1268 | $1286 | -1% |
| 2025-12-10 | Wells Fargo | $1200 | $1100 | +9% |
| 2025-12-04 | BMO Capital | $1200 | $1100 | +9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | main | Buy |
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-12-04 | BMO Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 20 ($1.49M) |
| Sells | 28 ($18559.12M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Lilly Endowment, Inc: 10.1% (-0.5%)
- Vanguard Group Inc: 8.6% (+0.7%)
- Blackrock Inc.: 7.0% (-0.2%)
- PNC Financial Servic: 5.4% (+0.1%)
- State Street Corpora: 3.7% (+0.6%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.8% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $18559M sold (28 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.98 indicates undervaluation relative to growth. Forward P/E 33.0x attractive for 38% earnings growth. Quality metrics strong (ROE 96%, ROA 18%, margin 31%). Balance sheet: $8.6B free cash flow. Revenue growth strong at 20% YoY. Analyst sentiment positive (2 raises, avg +9%). Insider selling cluster ($18559.1M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $966.2B |
| Beta | 0.37 |
| 52W Range | $623.78 - $1111.99 |
| Short Interest | 0.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.98 |
| Forward P/E | 33.0 |
| Current P/E | 45.5 |
| YoY Growth | 37.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 3.9% to 0.0% (-3.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.0pp (needs >3.0% for momentum thesis). MRS_5 (-0.1%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +DLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.04% (CS: 75) | Neutral |
| RSI_14 | 64.3 | Neutral |
| MACD Histogram | -0.10 | Bearish |
| vs SMA20 | 1.034x | Above |
| vs SMA50 | 1.104x | Above |
| vs SMA200 | 1.310x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $1077.52
- **Stop Loss:** $1024.36 (4.9% risk)
- **Target:** $1130.68 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 24
- **Position Value:** $25,860.48
- **Portfolio %:** 25.86%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-05 (Est: $7.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.89 | $7.02 | +19.1% |
| 2025Q2 | $5.59 | $6.31 | +12.9% |
| 2025Q1 | $3.54 | $3.34 | -5.7% |
| 2024Q4 | $5.07 | $5.32 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*